LY3200882 is an orally active TGFbeta inhibitor. LY3200882 targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells.
TGF-beta/Smad Inhibitors Related Products:
SB431542; LDN-193189; Galunisertib; LY2109761; SB525334; SB-505124; GW788388; LY364947; RepSox; K02288; A-83-01; LDN-212854; PD169316; ITD-1; Dorsomorphin; Dorsomorphin 2HCl; Kartogenin